title: Bevacizumab for occult subfoveal neovascularization in age-related macular degeneration.
abstract: OBJECTIVE
  To report on the treatment of exudative age-related macular degeneration by intravitreal bevacizumab (Avastin).
  
  
  METHODS
  A 78-year-old patient experienced a progressive loss of visual acuity in her right eye due to an occult subfoveal neovascular membrane in age-related macular degeneration. She received an intravitreal injection of 1.5 mg bevacizumab.
  
  
  RESULTS
  Within 4 weeks after the injection, visual acuity improved from 0.40 to 0.60 with complete resolution of subretinal and intraretinal leakage and edema as shown on optical coherence tomography. Pre-existing metamorphopsias disappeared. Intraocular pressure remained in the normal range. During the follow-up, there were no sings of intraocular inflammation or any other intraocular pathology induced by the intravitreal injection.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab may potentially be helpful in the treatment of exudative age-related macular degeneration and may deserve further evaluation.
authors.affiliation: Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany. Jost.Jonas@augen.ma.uni-heidelberg.de
authors.forename: J B
authors.initials: JB
authors.lastname: Jonas
authors.forename: B
authors.initials: B
authors.lastname: Harder
authors.forename: U H
authors.initials: UH
authors.lastname: Spandau
authors.forename: B A
authors.initials: BA
authors.lastname: Kamppeter
authors.forename: T
authors.initials: T
authors.lastname: Libondi
authors.forename: G
authors.initials: G
authors.lastname: Sauder
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005122:Exudates and Transudates; D005260:Female; D005500:Follow-Up Studies; D005584:Fovea Centralis / Q000473:pathology*; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab